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Abstract 
Protective immunity in tuberculosis (TB) is subject of debate in the TB research community, as 
this is key to fully understand TB pathogenesis and to develop new promising tools for TB 
diagnosis and prognosis as well as a more efficient TB vaccine. But in our search for a clearly 
defined protective immune response, the complexity of balancing TB immunity has to be 
considered including different components known to modulate cell-mediated immunity such as 
effector cell and regulatory cell interactions at the local site of infection. Intensified research 
around the microbiome and how this modulate Mtb-specific immunity in the lung may also 
enhance our understanding of TB disease development. Furthermore, common co-morbidities 
such as HIV, helminthes and diabetes may skew protective TB immunity towards pathogenic and 
regulatory responses. In this review, we summarize some of the current knowledge on protective 
immunity in TB and how this can be modulated by regulatory immune cell subsets, associated 
co-morbidities and the human microbiome.  
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Introduction 
Mycobacterium tuberculosis (Mtb) is one of the most successful pathogens, infecting one-fourth 
of the world population [1]. Although only ~5% of infected individuals do develop active 
tuberculosis (TB), the disease burden and transmission are major global health problems. So, 
what is required from the human immune system to combat persistent and inflammatory bacteria 
such as Mtb? Numerous attempts have been made to describe and map protective immunity in 
TB. Insights in protective mechanisms is required in order to develop new therapeutic strategies, 
a protective vaccine, and to be able to follow disease development as well as successful therapy. 
TB is a complex disease in that most Mtb-exposed individuals contain the infection in a latent 
state, meaning the bacteria are not cleared from infected sites but the host manages to mount an 
immune response efficient enough to contain the infection. Perturbations in this delicate balance 
of immune control may have detrimental effects and may be the result of many host factors, 
including changes in the microbiome, host metabolism and maybe even ageing, but also 
exposure to other pathogens as well as suppression mediated by regulatory T (Treg) cells or 
other immune cell subsets [2, 3]. Failure to control TB infection results in active disease, ranging 
from local Mtb infection in the lung or other organs, to disseminated and advanced disease 
including severe, irreversible immunopathology. Hence, TB immunity can be divided into early 
and late stages; from exposure to immunity in latent infection and progressive disease, and 
vaccine-induced immunity. Since Mtb is an intracellular bacterium, protective immunity is 
dependent on cell-mediated responses conducted by innate and adaptive cells, including 
macrophages and dendritic cells (DCs) and T-cells. Many different subsets amongst these cells 
have been identified and the heterogeneity in surface molecules as well as secreted effector and 
signaling molecules is large. Linking specific phenotypes and signaling pathways to function is 
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key and to understand how these can change depending on the stage of infection, the Mtb strain, 
the local tissue environment and level of inflammation.  
 
Mtb infection may already induce natural protection by itself, since a relatively low proportion of 
infected individuals will develop active TB disease during their life-time. Also Bacillus 
Calmette-Guerin (BCG), the only currently available vaccine against TB and the mostly 
distributed vaccine in the world, does protect infants and young children against severe forms of 
disease although BCG is less efficient in adults. The immunology of BCG vaccination has been 
discussed in detail recently [4], illustrating the complexity of BCG-induced immunity and even 
further illustrating our lack of understanding of protective responses. To complicate things 
further, the microbiota in the lung as well as the gut may interact with and affect the potency of 
Mtb-specific T-cell responses [5]. Likewise, concomitant infections, such as HIV and helminths, 
or other conditions including host metabolism, most extremely represented in patients with 
diabetes, could modify the immune responses and thereby reduce the host´s ability to fight Mtb 
infection [6]. Host immune responses have been analysed in various stages of Mtb infection, 
disease and upon vaccination. TB immunity may vary significantly depending on the time since 
infection or BCG vaccination. In this review, we discuss some of the current knowledge of 
protective immune responses in TB and how these are modulated (Figure 1). 
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Effector cells subsets involved in protective TB immunity 
 
Protective CD4+ Th1 cells 
Although it is known that both CD4+ and CD8+ T-cells mediate protection against Mtb [7], the 
diverse phenotypes of protective T-cells are mostly undefined. The strongest evidence for a 
significant contribution of CD4+ T-cells in TB control derives from the human 
immunodeficiency virus (HIV) field [8, 9]. Rapid loss of memory CD4+ T-cells in simian 
immunodeficiency virus (SIV) infection enhanced reactivation of latent TB [10] and early HIV-
mediated depletion of Mtb-specific Th1 cells is also prominent in individuals with latent TB 
[11]. A gradual decline in cellular immunity increased the risk of poorly-organized TB 
granuloma formation and progression of TB disease in HIV-infected individuals [12]. 
Accordingly, both human data [13] and experimental animal models [14] suggest that interferon- 
IFN- signaling and CD4+ T-cells producing IFN- are of central importance in TB. A critical 
role of the type I cytokine pathway, comprised of IFN-γ and interleukin-12 (IL-12) signaling, in 
the defense against mycobacterial infections has been demonstrated in patients with defects in 
these pathways who succumb with unusual mycobacterial infections [15]. In addition, IFN- 
disrupted mice are highly susceptible to sub-lethal doses of M. bovis infection as shown by the 
absence of nitric oxide (NO)-production in BCG-infected macrophages [16]. Thus, IFN-γ 
production has been the hallmark of anti-mycobacterial immunity and has been analysed in great 
detail. IFN-γ producing cells have been enumerated extensively in individuals with latent TB, 
active TB disease and following BCG vaccination. Likewise, the significance of tumor necrosis 
factor- (TNF- has been confirmed in mice [17] and in patients with autoimmune disorders 
who have a greatly enhanced risk to reactivate latent TB infection following anti-TNF therapy 
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[18]. The widely accepted model is that particularly IFN--producing CD4+ T-cells activate 
bactericidal effector mechanisms in Mtb-infected macrophages and other immune cells while 
TNF- may be more involved in the structural organization and cellular recruitment to the TB 
granuloma [19]. In contrast, IL-4-producing CD4+ Th2 cells are typically involved in antibody-
mediated immunity that contribute less to intracellular control of Mtb growth [20, 21].  
 
From the other side of the coin, many studies report that IFN--producing CD4+ T-cells are not 
reliable as immune correlates of protection in either murine [22, 23] or human TB [24]. 
Although IFN-γ positive cells are readily detected in TB patients, this may not correlate with 
protection against disease but rather indicate the presence of a mycobacterial infection or prior 
vaccination (Figure 2). Thus, even if Mtb can induce a strong T-cell response and critical 
production of IFN-γ, this may not be sufficient to execute protective responses. The quality of 
the response ie. co-expression with other imperative effector functions, is most likely also 
important. Production of multiple Th1 cytokines (IFN-, TNF-, IL-2) by the same T-cells, so 
called multifunctional T-cells, were considered a better correlate of protective efficacy in TB 
[25]. Moreover, increased mortality in TB/HIV co-infected patients occurs independently of 
CD4+ T-cell counts [26], suggesting that protective immunity can also involve other players. 
Human [27-29] and non-human primate [30] studies support a more prominent role for CD8+ 
T-cells, which are capable of producing cytolytic and antimicrobial effector molecules such as 
perforin and granulysin [31]. But also non-classical CD8+ T-cells [32-34] and γδ T-cells [35] 
as well as natural killer (NK) cells [36] and natural killer T-cells (NKT) cells [37] may possess 
potent protective capacity in TB [38].  
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Although, multifunctional T-cells simultaneous producing IFN-γ, TNF-α and IL-2 have been 
associated with TB protection, and despite induction of these cells by multiple vaccines and 
vaccine candidates, these cells were also abundantly present in patients with pulmonary TB 
[39]. Moreover, no correlation between induction of multifunctional T-cells and BCG induced 
protection in young infants was observed [40]. In contrast, the risk to develop TB disease in 
these young infants was associated with an increased circulation of activated CD4+ T-cells, 
suggesting a possible contribution of early immune activation to disease susceptibility [41]. 
Intriguingly, stronger cellular responses were detected as pre-activated lymphocytes and 
increased Th1 cytokine production but impaired macrophage activation in bronchoalveolar 
lavage (BAL) from individuals with latent TB compared healthy exposed individuals [42]. The 
balance in protective versus pathogenic CD4+ T cells responses in different phases of TB 
infection and disease will certainly be an interesting subject for further exploration. 
 
To understand how protective T-cell responses are induced, we also need to learn more about the 
interaction between effector T-cells and antigen presenting cells (APCs) at local sites of Mtb 
infection. While appropriate expression of cytokines and antimicrobial molecules is critical for 
T-cell function, efficient migration is also key to ensure trafficking and proper localization of 
protective cells into TB granulomas where Mtb-infected macrophages reside. Previous in vivo 
findings suggested that limited Mtb-antigen presentation and/or recognition within granulomas 
failed to support a high frequency of prolonged effector T-cell-APC interactions, which resulted 
in a muted T-cell response [43]. Moreover, it has been shown that the onset of protective CD4+ 
Th1 responses in vivo in the lung are delayed [44, 45]. Therefore, not only the quality, magnitude 
and localization, but also the timing of the T-cell response is important to secure effective early 
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protection. Thus, we need to discover the nature of protective effector/memory T-cells and also 
how these cells are induced and regulated in the inflamed milieu. 
 
Protective CD4+ Th17 cells 
Th17 cells or CD4+ T-cells that secrete IL-17 are a pro-inflammatory subset frequently 
associated with autoimmune diseases but also associated with protective immunity in TB [46]. 
Genetic polymorphisms of IL-17 may be associated with genetic susceptibility to TB disease, but 
this also depends on the ethnicity of the individuals [47]. The requirement for IL-17 in early 
protective responses may also depend on the virulence of the Mtb strain [48]. Apart from Th17 
cells, γδ T-cells [49] as well as mucosal-associated invariant T-cells (MAIT) cells [50] may 
contribute to production of IL-17 during TB protection. In patients with active TB disease, 
reduced frequencies of IL-17 producing CD4+ T-cells [51, 52] and also MAIT cells [50] were 
detected compared to healthy exposed individuals. Moreover, Th17 cells, nor IL-17, were hardly 
detected at the site of disease, suggesting that TB progression is associated with low Th17 
responses [53]. Successful treatment of active TB patients resulted in increased frequencies of 
Mtb-specific Th17 cells [54]. Similarly, transfer of Th17 cells from BCG vaccinated mice to 
recombinase activating gene (RAG) -/- mice induced IFN-γ-independent protection against Mtb 
infection, although this effect was also associated with enhanced local neutrophil-mediated 
inflammation [55]. Contrary, IL-17A-/- mice showed increased bacterial burden and impaired 
granuloma formation in the lungs that correlated to reduced survival upon Mtb infection [49].  
Deficient granuloma formation could be due to reduced IFN- and TNF- in the chronic stage 
[49]. IL-17 may also ameliorate TB disease severity by limiting the development of hypoxic 
granulomas [56]. Others have also shown that IFN-γ produced by Th17 cells is involved in 
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mediating protection and that localisation of the Th17 cells in close proximity with the 
macrophages is critical for protection [57].  Interestingly, the activity of Th17 cells may be 
down-regulated by Mtb-infected DCs recruiting IL-10-secreting neutrophils [58]. Although it has 
also been reported Mtb infected DCs are poor inducers of IFN- while enhancing IL17-
producing CD4+ T cells [59], suggesting that Mtb targets DCs to skew the immune responses 
away from protective IFN-γ. 
 
Vaccination studies in mice have shown that vaccines inducing stronger Th1 and Th17 responses 
also had a higher protective efficacy against Mtb challenge [60]. Accordingly, concomitant 
induction of IFN-γ and IL-17 was required to induce protection against Mtb infection in vivo, 
whereas induction of IFN-γ alone was not sufficient [61]. Likewise, balanced Th1 and Th17 
responses were correlates of protective host responses in cynomolgous macaques [62]. In 
humans, concomitant infections with other pathogens such as hookworms, alter the frequency of 
protective Th17 cells that may promote disease progression [63]. Altogether, most of these data 
show that IL-17 producing T-cells contribute to the protective response against Mtb. However, a 
balanced Th17 response is critical to prevent excess neutrophil influx resulting in inflammation 
and pathology in the Mtb-infected lung. The debate is ongoing whether IFN-γ is involved in the 
IL-17-mediated protective responses, but this may depend on experimental variables such as the 
model system or Mtb strains used as well as timing of the response. 
 
Protection mediated by unconventional T cell subsets 
In addition to multifunctional cytokine producing T-cells, T-cells producing multiple cytolytic 
effector molecules have been described, so-called polycytotoxic T-cells. In particular, lipo-
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arabinomannan (LAM) responsive T-cells with a polycytotoxic phenotype correlated with the 
capacity to control mycobacterial growth in vitro [64]. LAM responsive T-cells are known as 
unconventionally restricted T-cells, since LAM is presented by CD1b and not by classical MHC 
molecules. Over the recent years multiple alternative antigen presentation molecules have been 
identified, and have been demonstrated to present Mtb-derived ligands to T-cells. Since these 
antigen presentation molecules are frequently non-polymorphic the responding T-cells are called 
‘donor-unrestricted T-cells’ (DURT) or unconventional T-cells [65]. This family comprises CD1 
restricted T-cells, MR1 restricted MAIT cells and HLA-E restricted T-cells that may play a role 
in early protective effector cell responses against mycobacterial infections, since these members 
can respond rapidly upon pathogen encounter [65].  
 
MAIT cells are present at increased frequencies in the human airways and thought to have a role 
in the early defense against pathogens such as Mtb because of their innate-like pattern 
recognition based activation. Patients with severe (bacterial) infections had decreased circulating 
MAIT cell counts, which may contribute to their increased susceptibility to secondary infections 
[66]. Reduced circulating MAIT cells have also been detected in TB patients, while local 
frequencies in the lung were increased [67]. This may suggests that MAIT cells migrate from the 
peripheral blood to sites of Mtb infection. Thus, a decrease in MAIT cells observed in TB 
patients as well as patients infected with non-tuberculous mycobacteria, correlated with disease 
severity [68]. Moreover, MAIT cells from TB patients were not activated to produce cytokines 
such as IFN- upon in vitro stimulation, which indicated that MAIT cells may be functionally 
impaired in TB [68]. Studies in on-human primates  also show that MAIT cells are activated in 
response to BCG vaccination as well as Mtb infection [69], however data on the relative 
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contribution of MAIT cells to protective TB immunity in non-human primates is still lacking. In 
mice, Mtb infection induced heterogeneous MAIT responses [70]. In particular, Vα19i-
Tg MAIT cells expressing CXCR3 and α4β1 were recruited to the lung and contributed to early 
protection [70], suggesting that MAIT cells may also have a protective role in murine TB. It 
would be of great interest to further explore MAITs as possible therapeutic targets in TB. 
 
Another alternatively restricted subset of CD8+ T-cells are the HLA-E restricted T-cells. In 
contrast to the HLA class Ia genes, HLA-E is virtually non-polymorphic, with a single amino 
acid difference discriminating the major variants. Another interesting property of importance for 
potential future vaccine targeting, is the lack of down-regulation by HIV [71]. HLA-E typically 
presents signal sequences of HLA-A,B,C alleles to prevent NK mediated lysis of healthy cells 
[71]. Alternatively it can also present sequences from intracellular pathogens including Mtb [71-
74]. Detailed characterization of these cells revealed a unique Th2 cytokine repertoire [75-77]. 
Compared to individuals with latent TB, patients with active TB disease had higher frequencies 
of Mtb specific HLA-E restricted cells that decreased over time during treatment [75-77]. 
Patients suffering from TB/HIV co-infection had the highest frequencies of HLA-E restricted 
cells [75]. Intriguingly, T-cell clones specific for several Mtb peptides had the capacity, not only 
to lyse Mtb-infected target cells, but also to reduce the outgrowth of intracellular Mtb [77]. The 
strong capacity of HLA-E restricted T-cells to restrict Mtb growth in infected cells suggests a 
protective role against TB. However, increased frequencies of HLA-E restricted T-cells were 
reported in patients with active TB compared to LTBI individuals, but this may be the result of 
the enormous amount of antigen released during TB disease that evokes these responses. Mtb 
infection studies in mice have shown that the murine homologue of human HLA-E, Qa-1, is 
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involved in protection, mostly through modulation of inflammation [78]. The induction of strong 
effector T-cells in combination with the low level of allelic variation and stable expression 
makes HLA-E a very interesting candidate for vaccine targeting. 
 
Protection mediated by trained immunity 
Initial priming of the immune system upon first mycobacterial contact seems increasingly 
important. Gene expression analysis revealed that BCG vaccination in young infants induced two 
dichotomous responses, likely involving differential monocyte activation [79]. Similarly, 
dichotomous responses to primary BCG vaccination were also observed in adults [80]. In mice, 
priming with live mycobacteria induced transient immunity in contrast to immunity induced with 
subunit vaccines, which was more long-lasting [81]. Characterization of the vaccine-induced T-
cells, revealed accelerated differentiation and inferior homing to the lung parenchyma by T-cells 
activated by live mycobacteria [81]. This illustrates that an early response, probably mediated by 
the innate immune system, is critical in the activation and education of adaptive immunity. Thus, 
more research to investigate early priming of immune triggers is warranted. Transient alterations 
upon pathogenic exposure may also induce trained innate immunity [82-85]. Trained immunity 
reflects a state of temporary innate immune memory, in which cells, generally monocytes, are 
epigenetically reprogrammed [82-85]. This concept was originally described upon BCG 
vaccination of naïve adults and resulted in temporal reprogramming of innate immune cells [82]. 
Training of innate immune cells also augments cytokine production against non-related 
pathogens. A recent study demonstrated that a sub-group of BCG-vaccinated individuals 
responded to the vaccine by effectively reducing mycobacterial growth in vitro [86]. This effect 
was associated with a stable and robust differential DNA methylation pattern that was not 
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observed in the BCG non-responders [86]. Studies in mice showed that BCG educated 
hematopoietics stem cells resulting in trained monocytes that efficiently combatted Mtb during 
subsequent infections (ref = kaufmann, cell 172, 176). Education at the level of hematopoietic 
stem cells is an interesting observation which may help explain the fact that training effects last 
longer than the life-span of individual monocytes or macrophages. 
The process of training by live mycobacteria is unknown, but may significantly affect or even 
skew subsequent immune activation. Indeed, we observed signs of trained innate immunity upon 
recent Mtb exposure, but not in more established infection or disease (Joosten et al, JCI, 2018, in 
press). Interestingly, not all donors that initially controlled BCG outgrowth also developed 
detectable adaptive immune responses against Mtb (Joosten et al, JCI, 2018, in press). Together 
these data suggest that the initial activation of the immune system may be key in mounting the 
capacity to cope with mycobacteria later in life. Moreover, immune responses may vary 
considerably over time following infection or in the process to active disease. Longitudinal 
follow up of Mtb-infected adolescents revealed that TB disease development was associated with 
sequential modulation of immunological processes [87]. Early changes involved alterations in 
Type I/II interferon signaling and complement proteins, and repression of Th17 cells [87]. This 
illustrates the importance of kinetics and sequential events in the immune response against TB. 
Thus, it is important to consider the time elapsed since infection when selecting clinical samples 
for immunological characterization.  
 
Functional read out of effector immune responses 
Overall, analysis of CD4+ and CD8+ T-cells have not yielded satisfactorily markers or correlates 
of protective immunity, therefore functional approaches have received increasing attention. In 
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vitro mycobacterial growth inhibition assays have been explored to determine the capacity of 
whole blood or PBMC samples to control the growth of live mycobacteria, mostly BCG [88, 89]. 
In these assays, samples collected after primary BCG vaccination had the capacity to control 
BCG outgrowth, but this effect was abrogated by a secondary BCG vaccination [90]. Also BCG 
vaccination of mice results in growth reduction of BCG after infection of bulk splenocytes in 
vitro [88, 91]. Mtb infection status did not influence the capacity of whole blood to control Mtb 
or BCG outgrowth, possibly due to the strong neutrophil activity in the whole blood based assay 
[92]. Recently it was shown that exposed individuals from contact investigations, had a 
remarkably well capacity to control BCG outgrowth (Joosten et al, JCI, 2018, in press). Control 
of BCG outgrowth was mediated by a non-classical monocyte population producing CXCL10 
and was the result of trained innate immunity (Joosten et al, JCI, 2018, in press). These 
functional assays will be interesting candidates to monitor vaccine-induced protection in future 
vaccination trials. Moreover, all samples with strong control of BCG outgrowth will be essential 
to decipher the mechanism of growth inhibition. 
 
Regulatory cell subsets involved in suppression of protective TB immunity  
 
Regulatory T (Treg) cells and other pathogenic T cell subsets 
Obviously, the ability of the host to mount protective TB immunity is a multifactorial event 
that is also dependent on the local induction and expansion of immune cells with regulatory 
properties (Table 1). Natural CD4+CD25+FoxP3+ Tregs (developed in the thymus) as well as 
induced CD4+FoxP3+ Tregs (generated outside the thymus) are the most well-characterized 
regulatory subsets [2]. CD4+CD25+ Treg cells were detected at a 3-fold increased level in 
blood from active TB patients and Tregs had the capacity to suppress Mtb-specific IFN- 
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production [93]. IL-10-produicng CD4+CD25+FoxP3+ Treg cells have been shown to be 
elevated at the site of infection in the lung and to suppress Mtb-specific effector T-cell 
proliferation [94]. In addition, a recent study demonstrated that CD4+CD25+FoxP3+ Treg cells 
were elevated in the peripheral blood and in the granulomatous TB lesions of patients with 
extensively drug-resistant TB (XDR-TB) compared to drug-susceptible and latent TB [95], 
suggesting that expansion of Tregs may be an immune evasion mechanism exploited by 
virulent Mtb strains. Moreover, compartmentalization of TB immunity was previously shown 
to be characterized by few cytolytic CD8+ T-cells expressing perforin and granulysin but 
increased CD4+FoxP3+ Treg cells producing TGF- in proximity of Mtb-infected 
macrophages inside human granulomas, which may prevent efficient killing of infected cells 
[96]. 
 
While Tregs have an important role in TB, there are also other pathogenic T cell subsets and a 
complex network of both innate and adaptive regulatory cells and inhibitory pathway that 
contribute to the overall control of immune homeostasis and protective responses in TB. To 
mediate protection, T-cells should also be able to persist and maintain essential protective 
functions in the inflammatory environment in the lung. In this context, terminally 
differentiated T-cells expressing killer cell lectin-like receptor G1 (KLRG-1) have been 
suggested to be pathogenic in TB as these cells are usually associated with reduced 
proliferative [97] and lung migratory [98] capacities, including a higher sensitivity to the 
inflammatory environment in the lung parenchyma and more likely to be found in the 
vasculature [81, 99]. Similarly, elevated expression of IL-27 has been detected in patients with 
active TB and accordingly, IL-27R-expressing T-cells are associated with higher KLRG-1 and 
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IFN- expression and consequently higher bacterial burden and reduced T-cell protection in 
Mtb-infected lungs [99]. KLRG-1-expressing CD4+ T-cells were recently demonstrated to 
have a multifunctional cytokine profile, which is consistent with the notion that 
multifunctionality may not always be protective [100]. In contrast, development of central 
memory CD4+KLRG1- T-cells producing IL-2, are associated with control of Mtb growth and 
prolonged protection [81, 101]. Other inhibitory receptors involved in reducing Th1 immunity 
in TB are programmed cell death protein-1 (PD-1) [97], lymphocyte activation gene-3 (LAG-
3) [102], T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) [103] and cytotoxic 
T-lymphocyte associated protein 4 (CTLA-4) [104]. Such immune checkpoint inhibitors may 
be targeted to amplify TB immunity, but may also contribute to pathology rather than 
protection [105]. 
 
Regulatory B (Breg) cells  
Similar to T-cells, B-cells can have functionally and temporally distinct roles in the control of 
immune homeostasis. B-cells are also a major cellular component of TB granulomas in humans, 
non-human primates, and mice [106, 107]. In contrast to effector B-cells, which can secrete 
cytokines to support the differentiation of either Th1 or Th2 cells, regulatory B-cells (Breg cells) 
can suppress the inflammatory potential of effector T-cells and alter the activity of APCs [108]. 
Accordingly, human CD19+CD24hiCD38hi Breg cells have the ability to suppress the 
differentiation of both Th1 and Th17 cells, and to promote the expansion of FoxP3+ Tregs with 
suppressive functions [109]. CD19+CD1d+CD5+ Bregs cells have been shown to be elevated in 
patients with active TB and specifically suppress Th17 responses, which may have a negative 
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impact on the clinical outcome of TB [110]. Such Breg cells are reduced upon successful anti-TB 
treatment, which restored Mtb-specific production of the Th17 cytokine IL-22 [111].  
 
In contrast, a recent study failed to detect an increase in different subpopulations of Bregs in 
either active or latent TB, but instead observed an increased frequency of IgD-CD27- atypical B-
cells that was normalized after successful anti-TB treatment [112]. Impaired B-cells correlated 
with poor cytokine production by T-cells, which could be mimicked by B-cell depletion in LTBI 
donors. Therefore, functional B-cells may be required to induce a proper cytokine production 
and T-cell activation in human TB. Similarly, B-cell activation was restored upon anti-TB 
treatment including expression of IL-5RA and apoptosis-inducing FasL, which may suggest that 
B-cells with regulatory properties have a protective role in TB [113]. Further studies addressing 
the relevance of Bregs and atypical B-cells and their relative contribution to the pathogenesis of 
human TB will be of significant interest. 
 
Tolerogenic DCs 
Although DCs are the most potent APCs involved in triggering naive T-cell responses, 
tolerogenic DCs can support the development of an immunosuppressive environment. Virulent 
Mtb promotes tolerogenic DCs that produce suppressive cytokines such as IL-10, IL-13, or TGF-
β but also inhibitory molecules including PDL1 and PDL2, CD103, TIM-3, arginase or 
Indoleamine 2,3-dioxygenase (IDO) [114], which effectively diminish Th1 activation and instead 
contributes to the generation of Tregs [115]. Mtb-treated human DCs have been shown to expand 
CD4+CD25+FoxP3+ Tregs via Toll like receptor 2 (TLR2)- and DC-SIGN–dependent induction 
of PD-L1 on the DCs [116]. Recently, a lot of attention has been devoted to the 
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immunosuppressive enzyme IDO that degrades the essential amino acid tryptophan, causing 
tryptophan deprivation that may result in growth  arrest of T-cells as well as decreased antigen 
uptake and down-regulation of costimulatory molecules on DCs [115]. Instead, an environment 
high in tryptophan metabolites favors expansion of CD4+FoxP3+ Tregs and thus IDO can cause 
immunosuppression both by growth factor starvation and by the direct action of the tryptophan 
metabolites. Increased levels of IDO have been detected in pleural fluid and serum from patients 
with TB pleuritis and pulmonary TB, respectively [117, 118]. Enhanced IDO activity in PBMCs 
from individuals vaccinated with the novel TB vaccine modified vaccinia Ankara expressing 
antigen 85A (MVA85A), were found to be inversely correlated to vaccine-induced IFN- 
responses, suggesting that IDO activity may impair the generation of a CD4+ T-cell memory 
response [119]. The exact role of IDO and tolerogenic DCs in the regulation of TB infection 
remains to be determined.  
 
Alternatively activated macrophages (M2) 
The macrophage is one of the most central immune cells in the regulation of TB infection as this 
is the primary host cell to be infected by Mtb. Macrophages are versatile cells that can be 
polarized to a spectrum of functional programs in response to exogenous signals such as cytokine 
stimulation [120]. Although macrophage differentiation is not linear, the heterogeneity of 
macrophage activation is simplified by the division into classically activated or M1 macrophages 
(inflammatory) and alternatively activated or M2 macrophages (anti-inflammatory) as well as 
regulatory or Mreg macrophages (immunosuppressive) [121]. The phenotype and function of the 
different macrophages subsets have mostly been studied in mice, while this is less clear in 
humans [122]. While M1 macrophages typically express inducible nitric oxide synthase (iNOS) 
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and trigger Th1 responses that is required in TB defense, M2 macrophages activate arginase 
(Arg1) and may be involved in the induction of Th2 and tissue repair responses [120]. 
Interestingly, iNOS and Arg1 uses the same cellular substrate, arginine, and thus directly 
competes for the total amount of arginine, making the relative expression of these enzymes an 
important determinant for macrophage-mediated killing of Mtb [123, 124]. IFN- and IL-4 are 
the main cytokines involved in M1 versus M2 activation, and therefore the Th1/Th2 balance at 
the site of Mtb infection may dictate the induction of local macrophage effector functions. 
Mycobacterial virulence factors may interfere with M1 polarization and instead promote 
polarization of alternatively activated M2 macrophages that maintain a poorly microbicidal state, 
which facilitate mycobacterial growth and intracellular persistence [125, 126]. Particularly Arg1-
expression thwarts macrophage effector function and thus elimination of Arg1 decreased 
bacterial loads in TB [127]. An in vitro TB granuloma model has demonstrated that macrophage 
polarization changes from M1 to M2 over time following Mtb infection [128]. Accordingly, M2 
macrophages were found to predominate both necrotic and non-necrotic granulomas from TB 
patients, while both M1 and M2 polarized macrophages were found in the non-granulomatous 
lung tissues [128]. It has been proposed that alveolar macrophages in the lung are inherently 
alternatively activated, offering a cell permissive for Mtb replication [129]. An 
overrepresentation of M2 macrophages in the TB infected lung, could fuel tissue remodeling and 
Mtb growth that results in reduced lung function observed in patients with untreated, progressive 
disease [124]. Thus, a balanced ratio of M1:M2 (iNOS/Arg1) macrophages present at the site of 
Mtb infection may be key to avoid subversion of immune control.  
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In addition to the direct permissive state of M2 macrophages, these can also contribute to the 
generation of CD25+FoxP3+ Treg cells [130], perhaps via production of IL-10 and TGF- [120]. 
Moreover, the inhibitory molecule IDO can be expressed in Mtb-infected macrophages in vitro 
[131] and in the macrophage-rich areas of pulmonary TB granulomas in vivo [132]. While IDO-
expression in murine macrophages failed to control Mtb infection in vivo [131], a recent study 
revealed that in vivo inhibition of IDO in non-human primates resulted in enhanced T-cell 
proliferation and bacterial control involving relocation of effector T-cells to the center of 
pulmonary granulomas [133]. A predominance of M2 or Mregs in the TB granuloma may 
promote local expansion of Treg cells and impair effector cell function and the host ability to 
control Mtb infection [134]. Thus, a shift in M1/Teffector cells towards M2(Mreg)/Treg cells 
could promote immunosuppressive pathways and bacterial persistence in local TB lesions [124]. 
 
Myeloid-derived suppressor cells (MDSC) 
Protective T-cell responses in TB may also be regulated by local induction of novel innate 
monocyte-like cells called myeloid-derived suppressor cells (MDSC) [135]. These cells have 
been well-described in the cancer field, but data from their role in chronic infectious diseases 
such as TB has just started to emerge. MDSCs increase after Mtb infection and are able to 
suppress CD4+ T-cell proliferation and cytokine production, CD8+ T-cell function and T-cell 
migration [136]. MDSCs can phagocytose Mtb bacilli and accumulate at the site of Mtb infection 
in the inflamed lung together with neutrophils, where they interact with granuloma-residing cells 
and contribute to pathological inflammation [137, 138]. In vivo depletion of MDSCs reduced 
Mtb burden and ameliorated TB disease [137]. Increased frequencies of MDSCs in TB patients 
were described to be associated with elevated Arg1 activity and IDO protein levels in plasma 
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samples [139], while IFN- could block MDSC activity by reducing expression of Arg1 [140]. 
CD14-CD11b+ MDSCs were reduced after anti-TB therapy, indicating these cells could be used 
as prognostic biomarkers in TB [141]. Identification of CD244hi MDSCs in patients with active 
TB have been shown to express high levels of iNOS that were inversely correlated with 
activation and effector function of CD4+ and CD8+ T-cells [142]. This may suggest that high 
local production of NO produced by MDSCs may inhibit Mtb-specific T-cell responses. The dual 
ability of MDSCs to induce both Arg1 as well as iNOS, may imply that also these cells can be 
divided into several subsets with different inhibitory functions.   
 
Major co-morbidities associated with reactivation and progression of active TB  
The risk to be infected with or reactivate TB is significantly enhanced by a number of disease 
conditions including HIV [143] and helminth infections [144] but also by metabolic disorders 
such as diabetes mellitus type 2 (DM2) [145]. An important risk factor for TB development is 
also common viral infections such as cytomegalovirus (CMV) [41]. Infants who develop TB in 
the first 2 years of life had increased IFN-γ production and CD8+ T-cell activation in response to 
CMV stimulation [146]. Viral infections may induce immune activation that was previously 
identified as a risk factor for TB disease development. However, the etiology and specificity of 
the interaction between viral infections and development of TB disease has to be determined. 
 
TB/HIV co-infection 
TB and HIV co-infection is well-known as the cursed duet as both pathogens are dependent on 
cellular immunity that is gradually destroyed in HIV infection. Clinical studies confirm that 
HIV increases the risk of TB and likewise, Mtb infection may exacerbate HIV infection [143]. 
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Thus, HIV induces functional changes in all T-cells, including Mtb-specific T-cells and 
macrophages but Mtb can also modulate immune cell function that enhances HIV replication. 
Part of the vicious cycle is initiated by activation and up-regulation of the HIV co-receptor 
CCR5 on CD4+ T-cells by Mtb [147]. This results in enhanced viral spread and simultaneously 
a more rapid HIV-induced depletion of Mtb-specific effector memory CD4+CCR5+ T-cells 
from mucosal sites including the lung [148], which is associated with reactivation of latent TB 
infection [10, 149]. Remaining Mtb-specific CD4+ T-cells are preferentially retained in the 
lung and possess a reduced capacity to produce Th1 cytokines at the site of Mtb infection 
[150, 151]. Accordingly, Mtb-specific cytolytic T-cell activity is severely impaired in HIV-
infected individuals resulting in reduced killing of mycobacteria-infected macrophages [152]. 
In addition, CD4+Foxp3+ Tregs  expressing high levels of CCR5 and the survival factor Bcl-2, 
have been shown to be productively infected by HIV at the site of Mtb infection in the pleural 
cavity, providing CD4+FoxP3+ Tregs with a survival advantage compared to CD4+FoxP3- T-
cells [153]. 
 
Within the granulomas, HIV has the ability to promote cellular dysfunctions on CD4+ and CD8+ 
T-cells and macrophages, causing profound necrosis, bacterial dissemination and TB reactivation 
[12, 143]. Reduced numbers of CD4+ T-cells have been found in granulomatous tissue of 
SIV/TB co-infected primates [10], which may partly explain deficient macrophage activation and 
enhanced intracellular Mtb growth. HIV-induced manipulation of Mtb-infected macrophages 
involves dampened Mtb-induced TNF- production and less TNF-induced apoptosis of infected 
cells [154]. This may result in reduced cellular recruitment and lack of granuloma formation 
evident in HIV-infected patients with progressive disease [12]. On the other hand, Mtb can 
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induce a proinflammatory environment at the site of infection that promotes HIV replication 
[155], which highlights the double-edged sword in TB/HIV co-infection. HIV may also 
contribute to Mtb pathogenesis by interfering with the DC-mediated immune control. HIV and 
Mtb co-infected human DCs showed reduced expression of co-stimulatory molecules CD40, 
CD80 and CD86 as well as pro-inflammatory IL-6, IL-1 and TNF-, resulting in impairment to 
stimulate IFN- production by CD4+ T-cells [156]. In line with these findings, it was recently 
demonstrated that CD40-dependent co-stimulation of DCs was crucial to initiate protective Th17 
responses in TB [157]. Qualitative changes in cytokine expression involving reduced Th1 
responses have previously been demonstrated in PBMCs from TB/HIV co-infected patients [158, 
159]. In contrast, transcriptional profiling of skin biopsies from the TST injection site, showed 
that TB/HIV co-infected patients with TST reactivity maintained Th1 responses but lacked 
immunoregulatory IL10-inducible responses that could promote pathological inflammation [160] 
such as IL-17-driven recruitment of neutrophils. Instead, a negative TST was associated with 
profound anergy of both innate and adaptive responses. Most likely, HIV-induced immune 
dysfunctions may be characterized by different mechanisms depending on the degree of HIV-
associated immunosuppression [12]. 
  
TB/type 2 diabetes (DM2) 
Host metabolism affects the functional capacities of the immune system, this is most exemplified 
in individuals with extreme metabolic dysregulation such as patients with type 2 diabetes. 
Patients with DM2 have a 3-fold increased risk to progress to TB disease [161]. Hyperglycemia 
and cellular insulinopenia may affect both macrophage and lymphocyte functions, leading to a 
diminished ability to contain Mtb [162]. Currently, there is an inconsistency regarding loss of 
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immune control in the progression of TB in DM2 patients; some studies suggest too little 
inflammation and Th1 activation while other studies imply that TB/DM2 is associated with 
enhanced cell-mediated immunity. In a mouse model of diet-induced DM2, it was recently 
shown that an increased number of inflammatory lesions was associated with a reduced 
proinflammatory cytokine response and suppressed phagocytosis and bactericidal capacity of 
alveolar macrophages infected with mycobacteria [163]. Monocytes from TB/DM2 patients have 
also been suggested to have an altered phenotype that may enhance TB susceptibility, i.e. an 
enhanced expression of CCR2 that could prevent monocyte migration to the site of Mtb infection 
[164]. Consistently, an impaired and delayed Th1 response and a concomitant reduction in NO-
expression is evident in TB infected mice with chemically induced type 2 DM [162, 165]. 
Moreover, diabetic TB patients have been shown to have a lower Th1 to Th2 cytokine ratio in 
peripheral blood [166]. Another study suggests that selective expansion of CD4+CD25+CD127- 
Treg cells in the lung of TB/DM2 patients compared to the peripheral blood, correlates to 
reduced IFN-g and increased IL-10 levels at the site of Mtb infection [167].  
 
Impaired control of diabetes has also been associated with  increased systemic levels of pro-
inflammatory cytokines (IL-1β, IL-6 and IL-18) as well as anti-inflammatory IL-10 [168]. 
Cytokine and transcriptional profiling of plasma and whole blood samples support findings on 
elevated levels of proinflammatory cytokines and chemokines known to promote neutrophilic 
inflammation [169]. Likewise, enhanced Th1 and Th17 responses have been detected in 
TB/DM2 patients [170], while the cytolytic activity including expression of CD107a, perforin 
and granzyme B was defective in CD8+ T-cells [171]. Consistent with this finding, central 
memory CD4+ and CD8+ T-cell frequencies displayed a positive correlation with fasting blood 
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glucose and HbA1c levels [172], whereas effector/memory T-cells that strongly expressing 
cytolytic effector molecules [173] were detected in reduced levels in TB/DM2 patients. Overall, 
these contradictory results warrant a more comprehensive analysis of aberrant lymphocyte as 
well as macrophage responses in TB/DM disease. 
 
TB/helminth co-infection 
The third most recognized TB associated co-morbidity is concomitant infection with helminths. 
Mtb and helminths induce Th1 and Th2 immunity, respectively, that are likely to have 
antagonistic effects in vivo. TB patients with concomitant helminth infections present with 
reduced frequencies of peripheral T-cells as well as more severe radiological findings of 
pulmonary TB disease [174]. Asymptomatic helminth infection was shown to be associated with 
increased Treg and Th2 responses and a lower rate of sputum smear positivity [175]. Although 
deworming with albendazole failed to improve clinical symptoms, there was a significant decline 
in eosinophils and IL-10 production along with weight gain observed in the deworming group 
compared to placebo three months post-treatment [176]. Accordingly, helminths induced an IL-
10 mediated inhibition of multifunctional CD4+ T-cells responses with potential protective 
efficacy in TB [177]. Diminished Th1 and Th17 responses and increased Treg cells have also 
been observed in individuals with latent TB and hookworm infection [63]. Accumulation of 
alternatively activated macrophages in the lungs of co-infected mice was dependent on the IL-
4Ra-signaling pathway, which resulted in a Th2 response that promoted intracellular persistence 
of Mtb [178].  Additionally, chronic worm infection reduced the immunogenicity of BCG as 
individuals dewormed prior to vaccination, possessed elevated IFN- and IL-12 production while 
untreated BCG-vaccinated subjects had an increased production of TGF- upon restimulation 
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with mycobacterial antigens in vitro [179]. Interestingly, the BCG-vaccinated cohort did not 
show enhanced classical Th2 immunity, suggesting that helminths could modulate protective TB 
immunity in other ways.  
   
The role of the host microbiome in modulating protective TB immunity 
Shaping the immune response 
The linings of the human body are colonized with hugh amounts of micro-organisms including 
the skin, intestine and airways, called the microbiome. A long-time these micro-organisms have 
been considered to be commensal, non-harmful but also non-meaningful. Although the 
contribution of various bacteria to degradation and absorption of nutrients in the gut was 
recognized, the effects on shaping the immune response were quite recently appreciated. Immune 
modulating capacities of the microbiome may also be relevant for the onset of TB but may also 
contribute to treatment efficacy. Gut bacteria fermentate fibres (large carbohydrates) into several 
short chain fatty acids (SCFA), including acetate (C2), proprionate (C3) and butyrate (C4). 
SCFA can modulate cellular processes, including gene expression, differentiation, proliferation 
and cell survival [180]. Differential expression of the receptors for SCFA on immune cells may 
explain the various effects on different cell types [180, 181]. Monocytes and macrophages 
exposed to SCFA generally have a more anti-inflammatory response, although opposing effects 
have also been published [180]. In general, SCFA induce a more tolerogenic T-cell profile, 
frequently with an augmented induction of Treg cells [180]. Since concentrations of SCFA are 
primary increased in the colon, this is largely reflecting increased Treg populations in the lamina 
propria [182]. Butyrate is the most powerful inducer of Tregs in the colon, likely through 
inhibition of histone deacetylases (HDAC) in the promotor region of FoxP3 [182].  
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SCFA not only mediate their effects in the intestinal system, several key components of SCFA 
metabolism have been shown to play a role in the lung as well. Receptors for SCFA are also 
expressed in the airways as well as on cells infiltrating the lungs and upper airways. Free fatty 
acid receptor 3 (FFAR3; GPR41) is the SCFA receptor that is key in regulating airway 
inflammation, and plays an important role in fibre-induced diminution of allergic asthma [181]. 
SCFA can induce increased IL-8 production by airway epithelial cells through FFAR3 [183]. 
Moreover, SCFA can reduce growth of pathogenic Pseudomonas in vitro [184]. Although the 
substrates for SCFA production in the lung are unclear, these data indicate that also the 
microbiome at the lung epithelial surface can contribute to locally increased concentrations of 
SCFA that modulate host immunity. 
 
Microbiome and TB 
A potential contribution of the host microbiome in the combat against TB has also been 
investigated. To obtain comparable results, it is critical to select appropriate clinical materials 
from particularly the control population, since in TB patient’s, samples from the oropharynx, but 
not nasal samples, mimicked sputum [185] and thus the former are the preferred sample. 
Although major phyla were not different between TB and controls, the relative abundances of 
particular taxa suggest disturbances in microbial communities [185]. Analysis of nasopharynx 
samples (induced sputa) of children with TB, revealed no significant differences in the 
microbiota of children with or without TB [186]. Others have analysed the microbial 
composition of sputum from pulmonary TB patients and indicated that these samples were more 
complicated, characterized by many foreign bacteria compared to respiratory secretions from 
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healthy individuals [187]. Phylogenetic analysis revealed more Proteobacteria and Bacteroidetes 
in TB samples and more Firmicutes in controls with similar coughing symptoms [188]. In 
contrast, another study reported that the relative abundance of Firmicutes and Actinobacteria 
was significantly higher in TB samples [189]. The presence of certain bacteria and the 
disturbance of the lung microbiota may be associated with not only the onset of TB but also 
disease recurrence and treatment failure [190]. Assessment of microbiota in BAL from TB 
patients revealed specific differences, with Cupriavidus as dominant genus, in lower respiratory 
tracts [191]. The microbiome of individuals with detectable proprionate levels in BAL had a 
relative abundance of anaerobic bacteria [192], which is in line with the hypothesis that SCFA 
are produced locally in the lung. Together, these data indicate that the microbiome locally in the 
airways is disturbed during active TB disease, however, the differences in study populations 
(adults vs children, different ethnic origins including differences in diet), clinical samples 
(nasopharynx, sputum, BAL) and analysis methods make it impossible to draw any major 
conclusions on the alterations in microbiota composition during TB disease. 
 
In addition to the local microbiome, also gut microbiomes have been investigated in patients 
with TB and in experimental animal models of TB. In mice, antibiotic disturbance of the gut 
microbiota increased survival and dissemination of Mtb, which could be restored with fecal 
transplantation [193]. Similarly, modified gut microbiota also resulted in failed immune control 
of Mtb [194], while pulmonary TB patients had increased diversity in their gut microbiome 
[195]. Feces from patients with recurrent TB was enriched with Actinobacteria and 
Proteobacteria, many of which are pathogenic [195]. In contrast, controls had more beneficial, 
commensal organisms of the Bacteroidetes phylum [195]. Furthermore, increased serum 
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concentrations of SCFA, the products of the commensal bacteria, were associated with increased 
TB susceptibility in HIV-infected individuals [192]. Butyrate inhibited IFN-γ and IL-17 
production in response to Mtb-antigen stimulation of PBMCs [192], in a HDAC dependent 
manner [196]. The host microbiome may not only influence host immunity through SCFA 
production and HDAC activation, recent data suggest also a contribution in the antigen repertoire 
of T-cells [197]. Antigen recognition of presumed Mtb epitopes was influenced by prior episodes 
of TB disease, but only in the relatively recent history (< 6 years) [197]. A specific set of 
epitopes was poorly recognized by CD4+ T-cells producing IFN-γ from donors with TB 
diagnosis and treatment in their recent history. These epitopes were poorly regulated in Mtb and 
had a very high degree of homology with epitopes in bacteria in the microbiome [197]. The 
authors claim that their recent TB antibiotic treatment has disturbed the composition of the 
microbiome such that these antigens are no longer presented to the immune system [197]. 
Indeed, several studies have demonstrated that anti-TB treatment affected the composition of the 
host microbiome, ie. chemotherapy depleted multiple immunologically significant commensal 
bacteria from stool [198]. The perturbation of the stool microbiome lasted for at least 1.2 years 
[198]. Experimental studies in mice revealed that each of the components of anti-TB therapy 
contributes to the observed dysbiosis, but rifampin and pyrazinamide have the largest effects 
[199].   
 
In conclusion, the interplay between Mtb and the microbiome is interesting but highly complex. 
Firstly, not only the local, airway, microbiome but also the gut microbiome influence activation 
of immune responses against Mtb. Secondly, prior disturbances in the microbiome may influence 
the susceptibility to Mtb infection but may also alter protective TB immunity. Finally, since Mtb 
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infection in experimental animals also altered the microbiome it renders a catch 22 on cause and 
consequence. Thus the interplay between the microbiome and TB deserves a more detailed, 
systematic investigation. 
 
 
Concluding remarks 
Effector responses against Mtb are diverse and multiple subsets contribute to the protective 
efficacy. Many different subsets have been associated with protection in experimental models of 
TB, however the lack of protective vaccines in humans limits validation in humans. Some key 
players are essential but not sufficient to execute TB protection such as IFN-γ. Recent data have 
suggested contributions of novel players in the combat against Mtb, including innate immune 
responses such as those resulting from trained innate immunity. 
 
However, induction of effector responses as such, and as friends from the human host 
perspective, will not be the only factor determining the outcome in the combat against the 
bacillus. Infection with Mtb also results in activation of many regulatory or modulatory immune 
subsets, the foes of the human host, and the balance between all of these determines the outcome 
of the infection. Moreover, many circumstances associated with health or disease influence the 
magnitude and power of the effector responses. The specific host related conditions such as the 
microbiome lining the body surface will modify the capacity of effector cells to respond to 
infection. Also host metabolic status, in the extreme in DM2, will affect functioning of the 
immune system. Similar co-existing infections with viruses, such as CMV or HIV, or parasites, 
such as helminths, will also modify the power of the immune system to respond to infection. 
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Timing may be a critical factor in particular with regard to the comorbidities as they may impact 
differentially during initial priming of the immune system as compared to recall stages of 
effector immunity.  
 
Thus, solely the induction of effector immunity, although absolutely required, may not be 
sufficient to combat complex pathogens such as Mtb that have the capacity to modify many host 
processes. We will have to elucidate further on the modulation of host immunity by Mtb and 
other concomitant conditions in order to identify novel strategies to combat this world-
threatening infection. 
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Table 1. Regulatory immune cell subsets with a potential role in TB 
Cell subset Suppressive mechanism(s) Potential detrimental effects  
in TB disease 
 
natural Treg (nTreg) 
induced Treg  (iTreg) 
 
- Suppressive cytokines 
- Inhibitory surface molecules 
- Cell cycle arrest 
- Apoptosis 
- IL-2 consumption  
- AMP-mediated suppression  
- Decreased APC maturation, 
antigen presentation and/or co-
stimulation. 
- Granzyme B-mediated killing 
  
 
Suppress Th1 and Th17 effector cell 
responses early in the infection, either by 
mechanisms that target effector T and 
NK cells or that target different APCs. 
Migration of Tregs from the periphery 
and/or expansion at the site of infection 
may enhance bacterial growth in local 
lesions. Promotes the induction of Bregs, 
tolerogenic DCs and Mregs. 
 
Regulatory B cells 
(Breg) 
 
- Suppressive cytokines 
- Death receptor-ligands 
 
 
Accumulation of Breg cells in lymphoid 
follicle-like structures in close proximity 
to TB lesions in the lung may counteract 
Th1, Th17 and macrophage functions 
and promote the recruitment of Treg and 
Mreg cells to the site of infection. IL-10 
production induces iTregs cells. 
 
 
Tolerogenic DCs 
 
- Suppressive cytokines 
- Inhibitory surface molecules 
- Immunosuppressive enzyme 
IDO 
 
Inhibits T cell proliferation and effector 
cell differentiation. May enhance 
expansion of Tregs at the local site of 
infection.  
 
 
Alternatively activated 
macrophages (M2) 
 
- Suppressive cytokines and 
chemokines 
- Inhibitory receptors 
- Arginase-mediated deposition of 
collagen. 
- Immunosuppressive enzyme 
IDO  
- Crosstalk with stromal cells 
 
Increased bacterial uptake promotes 
intracellular growth. Support immune 
polarization of Th2 responses that 
counteract Th1 immunity and increase 
tissue remodeling and repair in the 
infected lung. Arg-1 counteracts iNOS 
and result in decreased antimicrobial 
activity of macrophages. May induce 
Tregs at the local site of infection.  
 
 
Regulatory macrophages 
(Mreg) 
 
 
- Suppressive cytokines 
- Inhibitory receptors 
- iNOS-mediated cytotoxicity 
- Immunosuppressive enzyme 
IDO 
 
 
Delete activated T cells and can suppress 
T cell proliferation using high levels of 
IL-10 and local induction of iNOS/NO or 
IDO. May promote the induction of both 
nTregs and iTregs. Enhanced suppressive 
activity in concert with myeloid-derived 
suppressor cells. 
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